P2X1 Receptor Inhibition and Soluble CD39 Administration as Novel Approaches to Widen the Cardiovascular Therapeutic Window☆☆☆
To access this article, please choose from the options below
☆ All authors contributed equally to this manuscript.
☆☆ C.Y.E. Fung and M.P. Mahaut-Smith were supported by the British Heart Foundation (PG/05/014). A.J. Marcus and M.J. Broekman were supported by NIH 5R37HL047073 and 5P01HL046403 and a MERIT REVIEW grant from the Department of Veterans Affairs.
PII: S1050-1738(09)00027-9
doi:10.1016/j.tcm.2009.01.005
© 2009 Elsevier Inc. All rights reserved.
